January 14, 2016 – RiMO Therapeutics Receives $250,000 Innovation Fund Award
The University of Chicago’s Innovation Fund selected RiMO Therapeutics in a competitive process as one of three companies to receive a combined award of $550,000 to support the translation of scientific discoveries for the marketplace.
RiMO intends to use these funds for its preclinical studies in order to launch its first in-human studies in the summer of 2016.
January 14, 2016 – RiMO Therapeutics Is University of Chicago’s First UCGo! Licensed Startup
RiMO Therapeutics became the first startup to execute a UCGo! Startup License with the University of Chicago. The program gives RiMO the license to the low-cost, low-radiation therapy developed by RiMO Chairman and CEO Wenbin Lin, James Franck Professor of Chemistry at the University of Chicago.
“Through the UCGo! program we were able to expedite the licensing process, which allowed us to continue our focus on developing this technology and growing the company,” said Lin. “We are eager to continue advancing this sophisticated platform, which could change the way we combat the most difficult to treat cancers.”
January 14, 2016 – RiMO Therapeutics Founder and Chairman Honored as Highly Cited Researcher and One of World’s Most Influential Scientific Minds
Wenbin Lin has been named one of Thomson Reuters’ Highly Cited Researchers in 2015 and included in their list of 2015 World’s Most Influential Scientific Minds, honors which are extended based on the number of citations his work has received by fellow researchers and which identify Dr. Lin as being among the most valuable and significant scholars in the field of Chemistry.
September 5, 2015 – RiMO Therapeutics Closes Angel Round Investment
“Elk Grove Village, Ill., September 5, 2015 — RiMO Therapeutics, a nano-pharmaceutical company commercializing the nanoscale coordination polymer (NCP) technology for radiotherapy and immunotherapy of recurrent and metastatic solid tumors, has closed angel round investment. The angel investors, friends and relatives of Dr. Wenbin Lin, share his passion for developing disruptive technologies for combating the most difficult to treat cancers. The angel round funds will be used to carry out IND-enabling preclinical studies in Fall 2015 and spring 2016. The angel round funds are expected to last through the first phase I trial on radiotherapy of recurrent head and neck cancer.
“I am grateful to my friends and families for their strong support and for their faith in our revolutionary technologies for cancer radiotherapy and immunotherapy,” said Wenbin Lin, Founder and Chairman of RiMO Therapeutics. “I am excited to embark on a new journey to shepherd the RiMO technology through the preclinical development phase.”